NasdaqGS:ICLRLife Sciences
ICON Revenue Review Ends With Restatement But Fundamentals Seen Intact
ICON (NasdaqGS:ICLR) recently completed an internal investigation into its revenue recognition practices.
The review resulted in a restatement of certain financial figures.
According to a featured investment analysis, the restatement has not affected ICON's margins, contracts, or business prospects.
For you as an investor, this centers on trust in the numbers that support ICON's role as a global provider of clinical research and related services. Revenue recognition reviews can raise...